{"id":60565,"date":"2024-02-28T06:55:40","date_gmt":"2024-02-28T06:55:40","guid":{"rendered":"https:\/\/medsname.com\/rosuline\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"rosuline","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/rosuline\/","title":{"rendered":"Rosuline"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">\u26a1 R\u0103spuns rapid \u2014 Ce este Rosuline?<\/h3>\n<p style=\"margin:0;\"><strong>Rosuline<\/strong> este un <strong>Comprimat de rosuvastatin\u0103 5 \/ 10 mg<\/strong> de la Torrent Pharma \u2014 un inhibitor de HMG-CoA reductaz\u0103 (statin\u0103) de \u00eenalt\u0103 intensitate, hidrofil. Statinele reduc evenimentele cardiovasculare <strong>Reducere de 20-30% pe mmol\/L a colesterolului LDL<\/strong> \u00een preven\u021bia primar\u0103, preven\u021bia secundar\u0103, diabet \u0219i popula\u021biile post-AVC. Rosuvastatina a fost introdus\u0103 de AstraZeneca \u00een 2003 ca. Statin\u0103 hidrofil\u0103; excretat\u0103 predominant neschimbat\u0103 \u00een fecale (10% renal, 90% biliar); metabolism CYP minimal (\u00een principal CYP2C9 moderat). Doza: 5-40 mg o dat\u0103 pe zi; 20-40 mg sunt doze de \u00eenalt\u0103 intensitate. Poten\u021b\u0103: rosuvastatina 20 mg reduce LDL-C cu 52%; 40 mg cu 55% \u2014 cea mai puternic\u0103 statin\u0103 pe mg. Doza tipic\u0103: o dat\u0103 pe zi, seara (pentru statine cu timp de \u00eenjum\u0103t\u0103\u021bire scurt) sau oric\u00e2nd pentru rosuvastatin\u0103 (timp de \u00eenjum\u0103t\u0103\u021bire suficient de lung \u00eenc\u00e2t momentul nu conteaz\u0103). Efecte secundare principale: simptome musculare (0,1-1% cu cre\u0219tere confirmat\u0103 a CK; p\u00e2n\u0103 la 10% dureri musculare nocebo), cre\u0219tere u\u0219oar\u0103 a transaminazelor (3%), diabet de nou\u0103 apari\u021bie la pacien\u021bii cu risc (~0,2 la 100 de ani-pacient). Contraindicat\u0103 absolut \u00een sarcin\u0103, boli hepatice active, antecedente de rabdomioliz\u0103. <strong>Crestor<\/strong>. Ce este Rosuline?.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Medicamentele noastre generice sunt procurate de la produc\u0103tori certifica\u021bi WHO-GMP \u0219i expediate la nivel mondial \u00een ambalaje discrete \u0219i simple \u2014 f\u0103r\u0103 denumirea medicamentului pe exteriorul coletului. Pl\u0103\u021bile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de pl\u0103\u021bi cu card reglementat \u2014 niciodat\u0103 \u201cMedsBase\u201d sau numele vreunui medicament). Accept\u0103m \u0219i criptomonede \u0219i transferuri bancare SEPA. Fiecare comand\u0103 este sus\u021binut\u0103 de Politica noastr\u0103 de Asigurare pentru Relivrare.<\/p>\n<h2 class=\"wp-block-heading\">What Is Rosuline?<\/h2>\n<p>Rosuline este un comprimat oral de rosuvastatin 5\/10 mg de la Torrent Pharma, furnizat \u00een cutii de 30-180 comprimate. Rosuvastatinul a fost introdus de AstraZeneca \u00een 2003 ca <strong>Crestor<\/strong>. Statin\u0103 hidrofil\u0103; excretat\u0103 \u00een principal neschimbat\u0103 \u00een fecale (10% renal, 90% biliar); metabolism CYP minimal (\u00een principal CYP2C9 moderat). Doza variaz\u0103 \u00eentre 5-40 mg o dat\u0103 pe zi; 20-40 mg reprezint\u0103 doze de intensitate ridicat\u0103.<\/p>\n<h2 class=\"wp-block-heading\">Cum ac\u021bioneaz\u0103 Rosuvastatinul<\/h2>\n<p>Rosuvastatinul inhib\u0103 <strong>HMG-CoA reductazei<\/strong>, enzima limitatoare a biosintezei hepatice a colesterolului. Efecte descendente:<\/p>\n<ul>\n<li><strong>Reducerea colesterolului intracelular \u00een hepatocite<\/strong> \u2014 declan\u0219eaz\u0103 activarea proteinelor de legare a elementelor sterolice (SREBP) \u0219i cre\u0219terea expresiei receptorilor LDL pe suprafa\u021ba hepatocitelor<\/li>\n<li><strong>Cre\u0219terea clearance-ului LDL-C circulant<\/strong> \u2014 principalul mecanism de sc\u0103dere a LDL<\/li>\n<li><strong>Reducere moderat\u0103 a trigliceridelor<\/strong> (10-20%) \u0219i cre\u0219tere moderat\u0103 a HDL (5-10%)<\/li>\n<li><strong>Efecte pleiotropice<\/strong> dincolo de sc\u0103derea LDL \u2014 reducerea inflama\u021biei vasculare (sc\u0103dere hs-CRP), \u00eembun\u0103t\u0103\u021birea func\u021biei endoteliale, stabilizarea pl\u0103cilor, reducerea reactivit\u0103\u021bii plachetare. Amploarea beneficiului clinic \u00een studiile dep\u0103\u0219e\u0219te ceea ce este explicat doar de modificarea LDL-C.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Doza Rosuline<\/h2>\n<p><strong>Preven\u021bie primar\u0103 (f\u0103r\u0103 eveniment CV anterior):<\/strong> \u00eencepe\u021bi cu 5-10 mg o dat\u0103 pe zi; ajusta\u021bi doza \u00een func\u021bie de riscul ASCVD pe 10 ani. Pentru diabetici sau risc ASCVD &gt;7,5%, dozele moderate (10-20 mg) sunt tipice.<\/p>\n<p><strong>Preven\u021bie secundar\u0103 (IM anterior, accident vascular cerebral, AOP sau CVD diabetic):<\/strong> terapie de intensitate ridicat\u0103 \u2014 20-40 mg o dat\u0103 pe zi. \u021aint\u0103 LDL-C &lt;1,8 mmol\/L (&lt;70 mg\/dL) conform ESC 2019 \u0219i &lt;1,4 mmol\/L (&lt;55 mg\/dL) pentru pacien\u021bii cu risc ASCVD foarte ridicat conform actualiz\u0103rii ESC 2021.<\/p>\n<p><strong>Hipercolesterolemie familial\u0103:<\/strong> statin\u0103 la doza maxim\u0103 tolerat\u0103 (de obicei 40 mg) adesea combinat\u0103 cu ezetimib\u0103 10 mg \u0219i\/sau inhibitor PCSK9 (alirocumab\/evolocumab\/inclisiran) pentru a atinge \u021bintele ghidurilor.<\/p>\n<p><strong>Administrare:<\/strong> o dat\u0103 pe zi, cu sau f\u0103r\u0103 m\u00e2ncare. Orice or\u0103 din zi \u2014 timpul de \u00eenjum\u0103t\u0103\u021bire de 19 ore \u00eenseamn\u0103 c\u0103 momentul administr\u0103rii nu afecteaz\u0103 semnificativ eficacitatea.<\/p>\n<p><strong>Monitorizare:<\/strong><\/p>\n<ul>\n<li><strong>Valori ini\u021biale:<\/strong> profil lipidic complet, teste hepatice (ALT), creatin-kinaz\u0103 (CK), HbA1c sau glicemie la stomacul gol, creatinin\u0103, hormon stimulator al tiroidelor (TSH) dac\u0103 nu au fost verificate recent.<\/li>\n<li><strong>4-12 s\u0103pt\u0103m\u00e2ni:<\/strong> repetarea analizelor lipidice pentru evaluarea r\u0103spunsului. Se a\u0219teapt\u0103 ca rosuvastatinul 20 mg s\u0103 reduc\u0103 LDL-C cu 52%; 40 mg cu 55% \u2014 cea mai puternic\u0103 statin\u0103 pe mg. Cre\u0219te\u021bi doza dac\u0103 \u021binta nu este atins\u0103.<\/li>\n<li><strong>Anual:<\/strong> lipide, teste hepatice (dac\u0103 nu sunt simptome). CK doar \u00een cazul pl\u00e2ngerilor musculare, nu \u00een mod rutinier.<\/li>\n<li><strong>Opri\u021bi \u0219i investiga\u021bi:<\/strong> CK &gt;10\u00d7 ULN, ALT &gt;3\u00d7 ULN \u0219i \u00een cre\u0219tere, durere muscular\u0103 neexplicat\u0103 persistent\u0103 cu CK &gt;5\u00d7 ULN, rabdomioliz\u0103 (urin\u0103 \u00eentunecat\u0103, sl\u0103biciune profund\u0103).<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Dovezi pentru Rosuvastatin<\/h2>\n<p><strong>JUPITER (2008)<\/strong> \u2014 rosuvastatin 20 mg la 17.802 pacien\u021bi cu LDL normal dar hs-CRP crescut a redus evenimentele cardiovasculare cu 44%; a extins indica\u021biile statinelor la riscul \u201cdeterminat de inflama\u021bie\u201d. <strong>ASTEROID (2006)<\/strong> \u2014 40 mg timp de 24 de luni a produs regresie m\u0103surabil\u0103 a pl\u0103cilor coronariene la examinarea IVUS. <strong>SATURN (2011)<\/strong> \u2014 rosuvastatin 40 mg versus atorvastatin 80 mg; rosuvastatin a avut o reducere u\u0219or mai mare a LDL, dar f\u0103r\u0103 un avantaj semnificativ \u00een regresie. <strong>HOPE-3 (2016)<\/strong> \u2014 rosuvastatin 10 mg pentru preven\u021bia primar\u0103 la pacien\u021bii cu risc intermediar a redus evenimentele cardiovasculare cu 24%.<\/p>\n<h2 class=\"wp-block-heading\">Utiliz\u0103ri aprobate \u0219i bazate pe dovezi<\/h2>\n<ul>\n<li>Preven\u021bia primar\u0103 \u0219i secundar\u0103 a bolilor cardiovasculare<\/li>\n<li>Riscul determinat de inflama\u021bie cu hs-CRP crescut (JUPITER)<\/li>\n<li>Pacien\u021bii predispu\u0219i la interac\u021biuni CYP3A4 (farmacologie mai simpl\u0103 dec\u00e2t atorvastatinul)<\/li>\n<li>Hipercolesterolemie familial\u0103<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Considera\u021bii practice<\/h2>\n<p>Mai pu\u021bine interac\u021biuni CYP3A4 dec\u00e2t atorvastatinul \u2014 un avantaj practic c\u00e2nd pacien\u021bii iau macrolide, azole sau anumite antiretrovirale. <strong>Doza limitat\u0103 la pacien\u021bii asiatici<\/strong> \u2014 FDA a redus doza ini\u021bial\u0103 pentru pacien\u021bii asiatici la 5 mg dup\u0103 ce studiile farmacocinetice au ar\u0103tat niveluri plasmatice de 2 ori mai mari. <strong>Monitorizarea creatin-kinazei \u0219i a testelor hepatice (LFT)<\/strong> ca \u0219i pentru toate stalinele.<\/p>\n<h2 class=\"wp-block-heading\">Efecte Secundare<\/h2>\n<p><strong>Frecvente (&gt;1%):<\/strong><\/p>\n<ul>\n<li><strong>Mialgie (dureri musculare)<\/strong> \u2014 deranjeaz\u0103 5-10% dintre utilizatori; simptome musculare asociate statinelor confirmate cu cre\u0219tere CK \u00een 0,1-1%. Component\u0103 mare de nocebo: studiul SAMSON (2020) nu a ar\u0103tat nicio diferen\u021b\u0103 \u00eentre statin\u0103 \u0219i placebo \u00een studii dublu-orb n-of-1 la mul\u021bi pacien\u021bi \u201cintoleran\u021bi la statine\u201d.<\/li>\n<li><strong>Cre\u0219tere u\u0219oar\u0103 a transaminazelor<\/strong> \u2014 3% prezint\u0103 cre\u0219tere ALT sub 3\u00d7 ULN; de obicei tranzitorie \u0219i nu necesit\u0103 modificarea dozei.<\/li>\n<li><strong>Diabet de nou-apari\u021bie<\/strong> \u2014 exces absolut ~0,2 la 100 de pacien\u021bi-an, \u00een special la pacien\u021bii prediabetici. Beneficiul cardiovascular dep\u0103\u0219e\u0219te cu mult riscul de diabet.<\/li>\n<li><strong>Cefalee, dispepsie, grea\u021b\u0103<\/strong><\/li>\n<li><strong>Disfunc\u021bie erectil\u0103<\/strong> (neobi\u0219nuit; mecanism necunoscut)<\/li>\n<li><strong>Tulbur\u0103ri de somn, cea\u021b\u0103 cognitiv\u0103<\/strong> (raportat dar nu consecvent \u00een studiile clinice randomizate)<\/li>\n<\/ul>\n<p><strong>Pu\u021bin frecvente, dar clinic importante:<\/strong><\/p>\n<ul>\n<li><strong>Rabdomioliz\u0103<\/strong> (10\u00d7 ULN.<\/li>\n<li><strong>Miopatie necrotizant\u0103 imunomediat\u0103<\/strong> \u2014 miopatie persistent\u0103 rar\u0103 care continu\u0103 dup\u0103 \u00eentreruperea statinei; mediat\u0103 de anticorpi anti-HMGCR. Necesit\u0103 tratament imunosupresiv.<\/li>\n<li><strong>Hepatit\u0103 sever\u0103 \/ leziune hepatic\u0103 indus\u0103 de medicament<\/strong> \u2014 rar; \u00eentrerupe\u021bi dac\u0103 ALT &gt;3\u00d7 ULN cu simptome sau tendin\u021b\u0103 ascendent\u0103.<\/li>\n<li><strong>Neuropatie periferic\u0103<\/strong> (rar)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Contraindica\u021bii<\/h2>\n<ul>\n<li><strong>Sarcin\u0103 \u0219i al\u0103ptare<\/strong> \u2014 statinele sunt contraindicate; colesterolul este necesar pentru dezvoltarea neurologic\u0103 fetal\u0103.<\/li>\n<li><strong>Boal\u0103 hepatic\u0103 activ\u0103<\/strong> sau ALT &gt;3\u00d7 ULN persistent neexplicat.<\/li>\n<li><strong>Rabdomioliz\u0103 anterioar\u0103 sau intoleran\u021b\u0103 sever\u0103 la statine<\/strong> confirmat prin provocare dubl\u0103-orb\u0103.<\/li>\n<li><strong>Inhibitori puternici concomitenti ai CYP3A4<\/strong> (pentru rosuvastatin): claritromicin\u0103, itraconazol, ritonavir \u2014 \u00eentrerupe\u021bi statina sau trece\u021bi la rosuvastatin\/pravastatin.<\/li>\n<li>Hipersensibilitate la statin\u0103.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interac\u021biuni medicamentoase<\/h2>\n<ul>\n<li><strong>Interac\u021biuni cu CYP2C9 \u0219i transportorul OATP1B1<\/strong> \u2014 ciclosporina, gemfibrozilul \u0219i unele antiretrovirale cresc nivelurile de rosuvastatin. Limita\u021bi doza de rosuvastatin la 5 mg cu ciclosporin\u0103; evita\u021bi cu gemfibrozil.<\/li>\n<li><strong>Suc de grapefruit<\/strong> \u2014 interac\u021biune minim\u0103 cu rosuvastatina (hidrofil\u0103; metabolism CYP3A4 minimal).<\/li>\n<li><strong>Fibrate (gemfibrozil, fenofibrat)<\/strong> \u2014 risc adi\u021bional de miopatie. Gemfibrozilul este cel mai problematic; fenofibratul este fibratul preferat pentru terapie combinat\u0103. Rezerva\u021bi combina\u021biile pentru tratamentul specializat al dislipidemiei.<\/li>\n<li><strong>Niacin\u0103 doze mari<\/strong> \u2014 risc adi\u021bional de miopatie. Doze mici de niacin\u0103 (1-2 g) sunt de obicei tolerate.<\/li>\n<li><strong>Warfarin<\/strong> \u2014 cre\u0219tere mic\u0103 a INR-ului la ini\u021bierea statinei; verifica\u021bi INR dup\u0103 1 s\u0103pt\u0103m\u00e2n\u0103 de la \u00eenceperea tratamentului. Nu este o contraindica\u021bie.<\/li>\n<li><strong>Digoxin\u0103<\/strong> \u2014 cre\u0219tere mic\u0103 a nivelului de digoxin\u0103 cu atorvastatin (P-glicoprotein\u0103); de obicei nu este semnificativ\u0103 clinic.<\/li>\n<li><strong>Alcool<\/strong> \u2014 consumul excesiv cre\u0219te riscul de leziuni hepatice. Consumul moderat este acceptabil.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Depozitare<\/h2>\n<p>P\u0103stra\u021bi Rosuline la temperaturi sub 25\u00b0C \u00een ambalajul original blister. Depozita\u021bi \u00eentr-un loc inaccesibil copiilor.<\/p>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3 class=\"wp-block-heading\">Trebuie s\u0103 iau Rosuline seara?<\/h3>\n<p>Nu \u2014 rosuvastatina are o semi-via\u021b\u0103 de 19 ore, suficient de lung\u0103 pentru a acoperi ciclul de ~24 de ore al sintezei nocturne de colesterol, indiferent de momentul administr\u0103rii. Administrarea diminea\u021ba cu alte medicamente este acceptabil\u0103. Regula \u201clua\u021bi statinele seara\u201d provine de la statinele cu semi-via\u021b\u0103 scurt\u0103 (simvastatin\u0103, lovastatin\u0103).<\/p>\n<h3 class=\"wp-block-heading\">Ce fac dac\u0103 am dureri musculare la administrarea Rosuline?<\/h3>\n<p>Efecte comune \u0219i rareori periculoase. Verifica\u021bi creatin-kinaza (CK). Dac\u0103 CK este normal\u0103, durerile nu sunt de obicei legate de statin\u0103 \u2014 studiul SAMSON (2020) a ar\u0103tat c\u0103 majoritatea pacien\u021bilor \u201cintoleran\u021bi la statine\u201d au avut dureri similare cu placebo \u00een studiu dublu-orb \u00eencruci\u0219at. Op\u021biuni: continua\u021bi statina cu suplimentare de vitamina D (dac\u0103 deficient), \u00eencerca\u021bi coenzima Q10 (dovezi slabe dar risc sc\u0103zut), schimba\u021bi statina (rosuvastatina are o rat\u0103 mai mic\u0103 de simptome musculare dec\u00e2t simvastatina \u0219i atorvastatina \u00een unele studii), reduce\u021bi doza sau adopta\u021bi administrare \u00een zile alternative. Opri\u021bi tratamentul doar dac\u0103 CK &gt;10\u00d7 ULN, simptomele sunt debilitante sau exist\u0103 sl\u0103biciune muscular\u0103 obiectiv\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Rosuline poate provoca diabet?<\/h3>\n<p>Statinile cauzeaz\u0103 o u\u0219oar\u0103 cre\u0219tere a riscului de diabet de tip 2 \u2014 aproximativ 1 caz suplimentar de diabet la 1.000 de persoane pe an, \u00een special la cei cu risc crescut de diabet (supraponderali, prediabet, istoric familial). Acela\u0219i tratament previne aproximativ 5-10 evenimente cardiovasculare la 1.000 de persoane pe an \u00een acelea\u0219i popula\u021bii \u2014 astfel \u00eenc\u00e2t beneficiul net este clar pozitiv. Nu \u00eentrerupe\u021bi statina doar din cauza riscului de diabet.<\/p>\n<h3 class=\"wp-block-heading\">Pot lua Rosuline cu suc de grapefruit?<\/h3>\n<p>Da \u2014 rosuvastatina are un metabolism CYP3A4 minimal, astfel \u00eenc\u00e2t interac\u021biunea cu grapefruitul este minor\u0103. Spre deosebire de atorvastatin\u0103, unde consumul regulat de grapefruit este descurajat.<\/p>\n<h3 class=\"wp-block-heading\">C\u00e2t timp va trebui s\u0103 iau Rosuline?<\/h3>\n<p>Indefinit, \u00een aproape toate cazurile. \u00centreruperea statinei determin\u0103 revenirea LDL-C \u00een c\u00e2teva s\u0103pt\u0103m\u00e2ni \u0219i pierderea protec\u021biei cardiovasculare \u00een c\u00e2teva luni. Statinele sunt terapie preventiv\u0103 pe termen lung pentru boala aterosclerotic\u0103, nu un tratament de scurt\u0103 durat\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Pot lua Rosuline \u00een timpul sarcinii?<\/h3>\n<p>Nu \u2014 statinele sunt contraindicate \u00een sarcin\u0103 \u0219i al\u0103ptare. Colesterolul este necesar pentru dezvoltarea neurologic\u0103 fetal\u0103; statinele trec prin placent\u0103. \u00centrerupe\u021bi statina \u00eenainte de o sarcin\u0103 planificat\u0103; dac\u0103 sarcina este neplanificat\u0103, opri\u021bi imediat \u0219i discuta\u021bi riscurile cu un specialist. Pacien\u021bii cu hipercolesterolemie familial\u0103 pot am\u00e2na de obicei terapia cu statine \u00een timpul sarcinii \u0219i al\u0103pt\u0103rii.<\/p>\n<h3 class=\"wp-block-heading\">Unde pot cump\u0103ra Rosuline online?<\/h3>\n<p>Pute\u021bi cump\u0103ra Rosuline (rosuvastatin 5 \/ 10 mg, 30-180 comprimate) de la MedsBase cu ambalaj discret \u0219i livrare la nivel mondial.<\/p>\n<h2 class=\"wp-block-heading\">Medicamente conexe pentru cardiologie \u0219i hipertensiune<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/aldactone\/\">Aldactone \u2014 Spironolacton\u0103 (antagonist MR neselectiv)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/amlopres-at\/\">Amlopres AT \u2014 Combina\u021bie de Amlodipin\u0103 + Atenolol<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/aten\/\">Aten \u2014 Atenolol (beta-blocant)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/ecosprin\/\">Ecosprin \u2014 Aspirin\u0103 75\/150 mg<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/eptus\/\">Eptus \u2014 Eplerenon\u0103 25\/50 mg (antagonist selectiv MR)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/lotensyl\/\">Lotensyl \u2014 Cilnidipin\u0103 10\/20 mg (blocant canale L+N tip CCB)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/high-blood-pressure-medication\/\"><strong>R\u0103sfoi\u021bi toate medicamentele pentru hipertensiune arterial\u0103<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 Dezaprobare medical\u0103.<\/strong> Aceast\u0103 pagin\u0103 are scop informativ \u0219i nu \u00eenlocuie\u0219te sfatul medical al unui medic calificat. Hipertensiunea, insuficien\u021ba cardiac\u0103 \u0219i aritmiile necesit\u0103 diagnostic, monitorizare \u0219i individualizarea dozei de c\u0103tre un medic \u2014 utiliza\u021bi \u00eentotdeauna beta-blocante sub \u00eendrumare medical\u0103.<\/div>\n<h3 class=\"wp-block-heading\">De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Rosuline este furnizat printr-un produc\u021btor certificat WHO-GMP cu documenta\u021bie COA complet\u0103. Livr\u0103m la nivel mondial \u00een ambalaje simple \u0219i discrete, iar fiecare comand\u0103 este acoperit\u0103 de <a href=\"\/ro\/medsbase-re-shipment-assurance-policy\/\">Politica noastr\u0103 de Reexpediere Garantat\u0103<\/a>. Descrierea tranzac\u021biei la plata cu cardul afi\u0219eaz\u0103 procesatorul de pl\u0103\u021bi reglementat (un procesator de pl\u0103\u021bi cu card reglementat), niciodat\u0103 \u201cMedsBase\u201d sau nume de medicamente.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Alternative conexe<\/h3>\n<p>Alte produse din <strong>Afec\u021biuni cronice<\/strong> pe care clien\u021bii le vizualizeaz\u0103 de asemenea:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/triohale-inhaler\/\">Triohale Inhalator<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/montair\/\">Montair<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/lomoother\/\">Lomoother<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/unicontin-e\/\">Unicontin-E<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/ventocortil\/\">Ventocortil<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Rosuline reprezint\u0103 comprimatele de rosuvastatin 5\/10 mg ale Torrent Pharma \u2014 cel mai potent statin pe mg. Ini\u021bial dezvoltat ca Crestor de AstraZeneca (2003). Hidrofil, cu eliminare predominant biliar\u0103 \u0219i metabolism CYP3A4 minimal \u2014 ceea ce \u00eel face statinul preferat pentru pacien\u021bii care iau macrolide, azoli sau antiretrovirale. Studiul JUPITER (2008) a extins indica\u021biile statinelor la popula\u021biile cu LDL normal \u0219i hsCRP ridicat. HOPE-3 (2016) a demonstrat beneficii \u00een preven\u021bia primar\u0103 la risc intermediar. Pacien\u021bii asiatici \u00eencep cu 5 mg (limit\u0103 farmacocinetic\u0103).<\/p>","protected":false},"featured_media":60566,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3260,3356,3953],"product_tag":[4882,4637],"class_list":{"0":"post-60565","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-heart-blood-pressure","9":"product_cat-high-blood-pressure-medication","10":"product_cat-high-cholesterol-treatments","11":"product_tag-rosuline","12":"product_tag-rosuvastatin","14":"first","15":"instock","16":"shipping-taxable","17":"purchasable","18":"product-type-variable","19":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/60565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=60565"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/60566"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=60565"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=60565"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=60565"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=60565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}